STAGEZERO LIFE SCIENC.
StageZero Life Sciences Ltd., a vertically integrated healthcare company, develops and commercializes proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications in North America and Western Europe. Its proprietary platform technology is Sentinel Principle, which identifies RNA-based biomarkers fr… Read more
STAGEZERO LIFE SCIENC. (61N1) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, STAGEZERO LIFE SCIENC. (61N1) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
STAGEZERO LIFE SCIENC. - Net Assets Trend (None–None)
This chart illustrates how STAGEZERO LIFE SCIENC.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for STAGEZERO LIFE SCIENC. (None–None)
The table below shows the annual net assets of STAGEZERO LIFE SCIENC. from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to STAGEZERO LIFE SCIENC.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
STAGEZERO LIFE SCIENC. Competitors by Market Cap
The table below lists competitors of STAGEZERO LIFE SCIENC. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Neola Medical AB
ST:NEOLA
|
$1.72 Million |
|
Lead Real Estate Co., Ltd American Depositary Shares
NASDAQ:LRE
|
$1.72 Million |
|
D'IETEREN (DJDA.SG)
STU:DJDA
|
$1.72 Million |
|
Grupo Mexicano de Desarrollo S.A.B
PINK:GMXDF
|
$1.72 Million |
|
WestKam Gold Corp
PINK:WKGFF
|
$1.72 Million |
|
OBAL11
SA:OBAL11
|
$1.72 Million |
|
Etga Group Ltd
TA:ETGA
|
$1.71 Million |
|
Algernon Pharmaceuticals Inc
OTCQB:AGNPF
|
$1.71 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in STAGEZERO LIFE SCIENC.'s equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares STAGEZERO LIFE SCIENC.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently STAGEZERO LIFE SCIENC. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares STAGEZERO LIFE SCIENC.'s net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $10,792,710,184
- Average return on equity (ROE) among peers: -33.38%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| STAGEZERO LIFE SCIENC. (61N1) | €- | N/A | N/A | $1.72 Million |
| Spermosens AB (publ) (9R5) | $23.64 Million | -27.17% | 0.09x | $517.28K |
| BML Inc (BMZ) | $81.13 Billion | 8.19% | 0.43x | $462.01 Million |
| Genomic Vision Société Anonyme (G09) | $3.07 Million | -162.85% | 1.21x | $711.54K |
| ICON Public Limited Company (IJF) | $1.85 Billion | 17.96% | 0.86x | $6.43 Billion |
| Adicon Holdings Limited (K0U) | $1.77 Billion | 2.65% | 1.64x | $138.53 Million |
| WuXi XDC Cayman Inc. (L74) | $1.48 Billion | 10.52% | 0.69x | $2.11 Billion |
| NanoRepro AG (NN6) | $57.61 Million | 51.59% | 0.37x | $16.84 Million |
| PERRIGO (PGO) | $24.67 Million | -167.93% | 0.99x | $6.37K |